PT  - JOURNAL ARTICLE
AU  - Eleonora Ghisoni
AU  - Matteo Morotti
AU  - Sara Colomer-Lahiguera
AU  - Manuela Eicher
AU  - George Coukos
AU  - Lionel Trueb
AU  - Massimo Di Maio
TI  - Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
AID  - 10.1136/jitc-2022-006082
DP  - 2022 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e006082
VI  - 10
IP  - 12
4099  - http://jitc.bmj.com/content/10/12/e006082.short
4100  - http://jitc.bmj.com/content/10/12/e006082.full
SO  - J Immunother Cancer2022 Dec 01; 10
AB  - Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials.